Citation: | YAN Wen-xin, ZHU Zheng, WU Yun-xiao, . Effectiveness of NPIs and vaccine coverage in the prevention and control of COVID-19 epidemic – an ecological comparative study among Australia, Korea, Singapore, Israel and India[J]. Chinese Journal of Public Health, 2022, 38(5): 597-603. doi: 10.11847/zgggws1138325 |
[1] |
Ferguson N, Laydon D, Nedjati Gilani G, et al. Report 9: impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand[J]. Imperial College London, 2020, 10(77482): 491 – 497.
|
[2] |
World Health Organization. Coronavirus (COVID-19) dashboard[EB/OL]. (2022 – 01 – 21)[2022 – 01 – 21].https://covid19.who.int/.
|
[3] |
Saxena SK, Kumar S, Ansari S, et al. Transmission dynamics and mutational prevalence of the novel severe acute respiratory syndrome coronavirus - 2 omicron variant of concern[J]. Journal of Medical Virology, 2022, 94(5): 2160 – 2166. doi: 10.1002/jmv.27611
|
[4] |
CDC. Nonpharmaceutical Interventions (NPIs)[EB/OL]. (2022 – 01 – 21)[2022 – 01 – 21].https://www.cdc.gov/nonpharmaceutical-interventions/index.html.
|
[5] |
Desvars-Larrive A, Dervic E, Haug N, et al. A structured open dataset of government interventions in response to COVID - 19[J]. Scientific Data, 2020, 7(1): 285. doi: 10.1038/s41597-020-00609-9
|
[6] |
Cowling BJ, Ali ST, Ng TWY, et al. Impact assessment of non - pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study[J]. The Lancet Public Health, 2020, 5(5): e279 – e288. doi: 10.1016/S2468-2667(20)30090-6
|
[7] |
Haug N, Geyrhofer L, Londei A, et al. Ranking the effectiveness of worldwide COVID - 19 government interventions[J]. Nature Human Behaviour, 2020, 4(12): 1303 – 1312. doi: 10.1038/s41562-020-01009-0
|
[8] |
Salathé M, Althaus CL, Neher R, et al. COVID - 19 epidemic in Switzerland: on the importance of testing, contact tracing and isolation[J]. Swiss Medical Weekly, 2020, 150: w20225.
|
[9] |
Lurie N, Saville M, Hatchett R, et al. Developing Covid - 19 vaccines at pandemic speed[J]. The New England Journal of Medicine, 2020, 382(21): 1969 – 1973. doi: 10.1056/NEJMp2005630
|
[10] |
Ritchie H, Mathieu E, Rodés-Guirao L, et al. Coronavirus Pandemic (COVID-19)[EB/OL]. (2022 – 01 – 21)[2022 – 01 – 21].https://ourworldindata.org/coronavirus.
|
[11] |
Chan JFW, Yuan SF, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person - to - person transmission: a study of a family cluster[J]. The Lancet, 2020, 395(10223): 514 – 523. doi: 10.1016/S0140-6736(20)30154-9
|
[12] |
Jeong E, Hagose M, Jung H, et al. Understanding South Korea's response to the COVID - 19 outbreak: a real - time analysis[J]. International Journal of Environmental Research and Public Health, 2020, 17(24): 9571. doi: 10.3390/ijerph17249571
|
[13] |
Wong JEL, Leo YS, Tan CC. COVID - 19 in Singapore – current experience: critical global issues that require attention and action[J]. JAMA, 2020, 323(13): 1243 – 1244. doi: 10.1001/jama.2020.2467
|
[14] |
Yoo JY, Dutra SVO, Fanfan D, et al. Comparative analysis of COVID - 19 guidelines from six countries: a qualitative study on the US, China, South Korea, the UK, Brazil, and Haiti[J]. BMC Public Health, 2020, 20(1): 1853. doi: 10.1186/s12889-020-09924-7
|
[15] |
Chen YY, Assefa Y. The heterogeneity of the COVID - 19 pandemic and national responses: an explanatory mixed - methods study[J]. BMC Public Health, 2021, 21(1): 835. doi: 10.1186/s12889-021-10885-8
|
[16] |
Von Seidlein L, Alabaster G, Deen J, et al. Crowding has consequences: prevention and management of COVID - 19 in informal urban settlements[J]. Building and Environment, 2021, 188: 107472. doi: 10.1016/j.buildenv.2020.107472
|
[17] |
Bhuyan A. Experts criticise India's complacency over COVID-19[J]. The Lancet, 2021, 397(10285): 1611 – 1612. doi: 10.1016/S0140-6736(21)00993-4
|
[18] |
Patel AK, Mukherjee S, Leifels M, et al. Mega festivals like MahaKumbh, a largest mass congregation, facilitated the transmission of SARS - CoV - 2 to humans and endangered animals via contaminated water[J]. International Journal of Hygiene and Environmental Health, 2021, 237: 113836. doi: 10.1016/j.ijheh.2021.113836
|
[19] |
Quadri SA, Padala PR. An aspect of Kumbh mela massive gathering and COVID - 19[J]. Current Tropical Medicine Reports, 2021, 8(3): 225 – 230. doi: 10.1007/s40475-021-00238-1
|
[20] |
Yang W, Shaman J. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination[J]. medRxiv, 2021,doi: 10.1101/2021.06.21.21259268.
|
[21] |
Mathieu E, Ritchie H, Ortiz-Ospina E, et al. A global database of COVID - 19 vaccinations[J]. Nature Human Behaviour, 2021, 5(7): 947 – 953. doi: 10.1038/s41562-021-01122-8
|
[22] |
Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS - CoV - 2 omicron variant in South Africa: a data linkage study[J]. Lancet, 2022, 399(10323): 437 – 446. doi: 10.1016/S0140-6736(22)00017-4
|
[23] |
Bernal JL, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study[J]. BMJ, 2021, 373: n1088.
|
[24] |
Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid - 19 vaccine in a nationwide mass vaccination setting[J]. The New England Journal of Medicine, 2021, 384(15): 1412 – 1423. doi: 10.1056/NEJMoa2101765
|
[25] |
Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid - 19 vaccine against the B. 1.1. 7 and B. 1.351 variants[J]. The New England Journal of Medicine, 2021, 385(2): 187 – 189. doi: 10.1056/NEJMc2104974
|
[26] |
Bernal JL, Andrews N, Gower C, et al. Effectiveness of Covid - 19 vaccines against the B. 1.617. 2 (Delta) variant[J]. The New England Journal of Medicine, 2021, 385(7): 585 – 594. doi: 10.1056/NEJMoa2108891
|
[27] |
Coccia M. High health expenditures and low exposure of population to air pollution as critical factors that can reduce fatality rate in COVID - 19 pandemic crisis: a global analysis[J]. Environmental Research, 2021, 199: 111339. doi: 10.1016/j.envres.2021.111339
|
[28] |
Tada T, Zhou H, Dcosta BM, et al. Partial resistance of SARS - CoV - 2 delta variants to vaccine - elicited antibodies and convalescent sera[J]. iScience, 2021, 24(11): 103341. doi: 10.1016/j.isci.2021.103341
|
[29] |
Chia PY, Ong SWX, Chiew CJ, et al. Virological and serological kinetics of SARS-CoV-2 delta variant vaccine breakthrough infections: a multicentre cohort study[J]. Clinical Microbiology and Infection, 2021,doi: 10.1016/j.cmi.2021.11.010.
|
[30] |
Nguyen KV. Problems associated with antiviral drugs and vaccines development for COVID - 19: approach to intervention using expression vectors via GPI anchor[J]. Nucleosides, Nucleotides and Nucleic Acids, 2021, 40(6): 665 – 706. doi: 10.1080/15257770.2021.1914851
|
[31] |
Eubank S, Eckstrand I, Lewis B, et al. Commentary on ferguson, et al. , "Impact of non - pharmaceutical interventions (NPIs) to reduce COVID - 19 mortality and healthcare demand"[J]. Bulletin of Mathematical Biology, 2020, 82(4): 52. doi: 10.1007/s11538-020-00726-x
|
[32] |
Patel MD, Rosenstrom E, Ivy JS, et al. The joint impact of COVID-19 vaccination and non-pharmaceutical interventions on infections, hospitalizations, and mortality: an agent-based simula-tion[J]. medRxiv, 2021,doi: 10.1101/2020.12.30.20248888.
|
[33] |
Miller NL, Clark T, Raman R, et al. Insights on the mutational landscape of the SARS - CoV - 2 omicron variant receptor-binding domain[J]. Cell Reports Medicine, 2021, 3(2): 100527.
|
[34] |
Garrett N, Tapley A, Andriesen J, et al. High rate of asymptomatic carriage associated with variant strain omicron[J]. medRxiv, 2022,doi: 10.1101/2021.12.20.21268130.
|
[35] |
Cele S, Jackson L, Khoury DS, et al. SARS-CoV-2 omicron has extensive but incomplete escape of pfizer BNT162b2 elicited neutralization and requires ACE2 for infection[J]. medRxiv, 2021,doi: 10.1101/2021.12.08.21267417.
|
[36] |
Davies MA, Kassanjee R, Rosseau P, et al. Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa[J]. medRxiv, 2022,doi: 10.1101/2022.01.12.22269148.
|
[37] |
Andrews N, Tessier E, Stowe J, et al. Duration of protection against mild and severe disease by covid - 19 vaccines[J]. The New England Journal of Medicine, 2022, 386(4): 340 – 350. doi: 10.1056/NEJMoa2115481
|
[38] |
Andrews N, Stowe J, Kirsebom F, et al. Effectiveness of COVID-19 vaccines against the Omicron (B. 1.1. 529) variant of concern[J]. medRxiv, 2021,doi: 10.1101/2021.12.14.21267615.
|
[39] |
吴俣, 刘珏, 刘民, 等. 新型冠状病毒Omicron变异株的流行病学特征及防控研究[J]. 中国全科医学, 2022, 25(1): 14 – 19.
|